Abstract
Epstein-Barr virus (EBV) is associated with several different types of aggressive non-Hodgkin lymphoma (NHL). Individuals with primary or secondary immunodeficiency are susceptible to developing B cell lymphoproliferation due to outgrowth of EBV-infected B cells that express type III latency characterized by expression of all nine latent-cycle EBV antigens. These cells would normally be susceptible to control by EBV-specific T cells, and strategies to restore EBV-specific immune responses may be effective therapeutically. EBV-associated lymphomas occurring in individuals who do not have a known immunodeficiency include NK and T malignancies with cytotoxic phenotypes, sporadic cases of B-NHL and lymphomatoid granulomatosis. These malignancies respond poorly to standard chemoradiotherapy, and immunotherapeutic or pharmacologic strategies targeting EBV are being explored.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 260-266 |
| Number of pages | 7 |
| Journal | Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program |
| DOIs | |
| State | Published - 2005 |
ASJC Scopus subject areas
- Hematology
Fingerprint
Dive into the research topics of 'Biology and treatment of Epstein-Barr virus-associated non-Hodgkin lymphomas.'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS